Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its second quarter 2021 financial results on August 11, 2021, before U.S. markets open. A conference call is scheduled for the same day at 8:00 a.m. EDT. Cerevel focuses on neuroscience diseases, with a diversified pipeline including five clinical-stage therapies targeting conditions like Parkinson's and epilepsy. The company emphasizes its commitment to unraveling brain mysteries, advancing R&D, and potential collaborations. Investors can access more information through the company's investor website.
- Cerevel has a diversified pipeline with five clinical-stage investigational therapies.
- Company focuses on significant neuroscience diseases, enhancing market potential.
- Forward-looking statements indicate uncertainty in clinical trial results and product approvals.
- Potential operational disruptions due to COVID-19 could affect timelines.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open.
Management will host a conference call to discuss second quarter 2021 financial results and recent business and pipeline updates on Wednesday, August 11, 2021 at 8:00 a.m. EDT. To access the call, please dial 833-665-0655 (domestic) or 702-495-1044 (international) and refer to conference ID 8947263.
A live webcast of the call, along with supporting slides, will be available on the investors section of Cerevel’s website at investors.cerevel.com. Following the live webcast, an archived version of the call will be available on the website.
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the timing of reporting of our second quarter 2021 financial results and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Form S-1 Registration Statement filed with the SEC on June 29, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Kate Contreras
Real Chemistry
kcontreras@realchemistry.com
Investor Contact:
Matthew Calistri
Cerevel Therapeutics
matthew.calistri@cerevel.com
FAQ
When will Cerevel Therapeutics report its second quarter 2021 financial results?
What is Cerevel Therapeutics' focus regarding its pipeline?
What time is the conference call to discuss Cerevel's financial results?
How can investors access the Cerevel Therapeutics conference call?
Where can I find the archived version of Cerevel's conference call?
